Benefits of CELMoDs over IMiDs in multiple myeloma
Benefits of CELMoDs over IMiDs in multiple myeloma Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, comments on the differences between cereblon E3 ligase modulators (CELMoDs) including iberdomide and CC-92480 and immunomodulatory imide drugs (IMiDs) in the treatment of multiple myeloma. Whilst these compounds appear structurally similar to IMiDs, they are significantly […]
Read More